The authors investigated the antihypertensive effect of sacubitril/valsartan (Sac/Val) when switching from other drugs and assessed whether brain natriuretic peptide (BNP) or plasma renin activity (PRA) before drug switching was a predictor of blood pressure lowering after switching to Sac/Val. In 92 patients with treated hypertension, clinic blood pressure, plasma BNP, and PRA were examined before and after switching to Sac/Val. Clinic systolic and diastolic blood pressures significantly decreased after drug switching to Sac/Val (p < .0001, respectively). The level before drug switching of BNP had no correlation with the change in systolic blood pressure (Δ-SBP) before and after switching to Sac/Val, but that of PRA was significantly correlated with Δ-SBP (r = .3807, p = .0002). A multiple regression analysis revealed that PRA before drug switching was an independent determinant of Δ-SBP. Our findings suggest that low PRA may become a useful marker to predict the antihypertensive effect of switching to Sac/Val in treated hypertensive patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466351 | PMC |
| http://dx.doi.org/10.1111/jch.14900 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma renin activity as a marker for predicting the antihypertensive effect of switching to sacubitril/valsartan in treated hypertensive patients: Usefulness in daily clinical practice.
J Clin Hypertens (Greenwich)
October 2024
Department of Cardiovascular Medicine, Ishikiriseiki Hospital, Higashiosaka, Japan.
The authors investigated the antihypertensive effect of sacubitril/valsartan (Sac/Val) when switching from other drugs and assessed whether brain natriuretic peptide (BNP) or plasma renin activity (PRA) before drug switching was a predictor of blood pressure lowering after switching to Sac/Val. In 92 patients with treated hypertension, clinic blood pressure, plasma BNP, and PRA were examined before and after switching to Sac/Val. Clinic systolic and diastolic blood pressures significantly decreased after drug switching to Sac/Val (p < .
View Article and Find Full Text PDFIn-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.
Eur Heart J
November 2024
Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Article Synopsis
- The study aimed to assess the effects of starting sacubitril/valsartan (Sac/Val) therapy during hospitalization for acute heart failure (AHF) on NT-proBNP levels in Japanese patients.
- It involved a randomized trial with 400 patients, comparing those who switched to Sac/Val versus those who continued standard therapy, measuring changes in NT-proBNP at 4 and 8 weeks.
- Results showed that the Sac/Val group experienced significantly greater reductions in NT-proBNP levels, particularly in patients with lower left ventricular ejection fractions, with no significant safety concerns noted.
Clinical Benefit of Sacubitril/Valsartan for Hypertensive Patients in Daily Practice and Predictors of Its Antihypertensive Effect.
Circ Rep
July 2024
Department of Cardiovascular Medicine, Ishikiriseiki Hospital Osaka Japan.
The blood pressure (BP)-lowering effect of sacubitril/valsartan (Sac/Val) is greater than that of angiotensin II receptor blockers (ARBs) but in in real-world clinical practice, Sac/Val is used in a variety of patterns other than switching from ARBs. In the present study we investigated the effects of Sac/Val on BP and biochemical parameters when switching from or adding it to various antihypertensive drugs and examined what factors could be predictors of the antihypertensive effect of Sac/Val. In 108 hypertensive patients treated with antihypertensive agents (including 4 naïve cases), clinic BP and various biochemical parameters were assessed before and after switching to/adding Sac/Val (200 mg/day).
View Article and Find Full Text PDFSacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients.
Life (Basel)
May 2023
Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy.
Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity remain uncertain; consequently, we sought to compare Sac/Val vs. standard medical therapy, in terms of effects on prognostically significant CPET parameters, in HFrEF patients during a long follow-up period.
View Article and Find Full Text PDFIntroduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).
ESC Heart Fail
August 2020
Cardiology, Cardiovascular Department, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
Article Synopsis
- The THESEUS study aimed to evaluate the shift from angiotensin converting enzyme inhibitors to sacubitril/valsartan (sac/val) in managing heart failure with reduced ejection fraction (HFrEF) within primary care settings.
- Conducted in Switzerland with 58 patients, the study measured patient characteristics, treatment transition, and maintenance over a six-month period, assessing outcomes like well-being and healthcare utilization.
- Findings indicated that transitioning to sac/val was achievable and safe in primary care, with 36.5% of patients reaching the target dose while experiencing improved overall health and reduced hospital visits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!